Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei

Rasmus Hare Jensen, Ulrik Stenz Justesen, Annika Rewes, David S Perlin, Maiken Cavling Arendrup

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

Resumé

Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.

OriginalsprogEngelsk
Publikationsdato10. maj 2014
Antal sider3
DOI
StatusUdgivet - 10. maj 2014
Begivenhed24th European Congress of Clinical Microbiology and Infectious Diseases - Barcelona, Spanien
Varighed: 10. maj 201413. maj 2014
Konferencens nummer: 24

Konference

Konference24th European Congress of Clinical Microbiology and Infectious Diseases
Nummer24
LandSpanien
ByBarcelona
Periode10/05/201413/05/2014

Fingeraftryk

anidulafungin
Mutation

Citer dette

Jensen, R. H., Justesen, U. S., Rewes, A., Perlin, D. S., & Arendrup, M. C. (2014). Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei. Abstract fra 24th European Congress of Clinical Microbiology and Infectious Diseases , Barcelona, Spanien. https://doi.org/10.1128/AAC.02367-14
Jensen, Rasmus Hare ; Justesen, Ulrik Stenz ; Rewes, Annika ; Perlin, David S ; Arendrup, Maiken Cavling. / Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei. Abstract fra 24th European Congress of Clinical Microbiology and Infectious Diseases , Barcelona, Spanien.3 s.
@conference{8f4d7a51f4db44c3bcf2f54ea3ff4961,
title = "Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei",
abstract = "Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.",
author = "Jensen, {Rasmus Hare} and Justesen, {Ulrik Stenz} and Annika Rewes and Perlin, {David S} and Arendrup, {Maiken Cavling}",
note = "Copyright {\circledC} 2014, American Society for Microbiology. All Rights Reserved.; null ; Conference date: 10-05-2014 Through 13-05-2014",
year = "2014",
month = "5",
day = "10",
doi = "10.1128/AAC.02367-14",
language = "English",

}

Jensen, RH, Justesen, US, Rewes, A, Perlin, DS & Arendrup, MC 2014, 'Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei' 24th European Congress of Clinical Microbiology and Infectious Diseases , Barcelona, Spanien, 10/05/2014 - 13/05/2014, . https://doi.org/10.1128/AAC.02367-14

Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei. / Jensen, Rasmus Hare; Justesen, Ulrik Stenz; Rewes, Annika; Perlin, David S; Arendrup, Maiken Cavling.

2014. Abstract fra 24th European Congress of Clinical Microbiology and Infectious Diseases , Barcelona, Spanien.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

TY - ABST

T1 - Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei

AU - Jensen, Rasmus Hare

AU - Justesen, Ulrik Stenz

AU - Rewes, Annika

AU - Perlin, David S

AU - Arendrup, Maiken Cavling

N1 - Copyright © 2014, American Society for Microbiology. All Rights Reserved.

PY - 2014/5/10

Y1 - 2014/5/10

N2 - Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.

AB - Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.

U2 - 10.1128/AAC.02367-14

DO - 10.1128/AAC.02367-14

M3 - Conference abstract for conference

ER -

Jensen RH, Justesen US, Rewes A, Perlin DS, Arendrup MC. Echinocandin failure case due to a yet unreported FKS mutation in Candida krusei. 2014. Abstract fra 24th European Congress of Clinical Microbiology and Infectious Diseases , Barcelona, Spanien. https://doi.org/10.1128/AAC.02367-14